

## CORRIGENDUM

### Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

#### Abstract

The authors wish to make corrections to their article:

Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. *Drugs in Context* 2019; 8: 212605. DOI: [10.7573/dic.212605](https://doi.org/10.7573/dic.212605)

#### Corrigendum

The authors regret that there are errors in their original paper.

1. The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).

##### Page 3, section on Berinert®

In 2009, the US FDA approved Berinert® (CSL Behring), a pasteurized plasma-derived C1-INH concentrate, available for intravenous (IV) administration in patients needing on-demand therapy. This drug was also not approved for short-term prophylaxis in the EU in 2013, but is used off-label for this purpose:

The following reference from the Head of Medicine website (EU approval document) should also be added to this statement:

[https://mri.cts-mrp.eu/Human/Downloads/DE\\_H\\_0481\\_003\\_PAR.pdf](https://mri.cts-mrp.eu/Human/Downloads/DE_H_0481_003_PAR.pdf)

##### Page 5, section on Haegarda®

C1-INH (SC) Haegarda®

Haegarda® and Berinert® 2000/3000 (CSL Behring) were approved (US and EU) ~~was approved by the FDA~~ in 2017 as the first subcutaneous C1 inhibitor concentrate, also indicated for self-administration, at the dose of 60 IU/kg twice weekly. ~~Nevertheless, the European Medicines Agency did not formally approve the marketing of the drug.~~<sup>29</sup>

2. Table 1 lists two products Berinert® and Haegarda® on separate lines; however, they should be grouped together as follows:

Drug name	Active substance	Type and action	Administration	Indication	T1/2
Berinert®, CSL Behring	C1-INH	Plasma-derived C1-INH concentrate pasteurized, nanofiltered	IV	On-demand, short-term prophylaxis	36–48 hours
Berinert® 2000/3000 (Haegarda® brand name in the United States and Canada)	C1-INH	Plasma-derived C1-INH concentrate pasteurized, nanofiltered	SC	Long-term prophylaxis	69 hours